Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology.
Omniose is an early stage biotechnological company.
Ceramedix Holding is a biotherapeutics company that develops antibody-based drugs with the aim of addressing novel diseases.
Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.
Truly Technologies develops biospecimen processing technologies for diagnostic, therapeutic and life science research applications.
Iaso Therapeutics develops vaccines to improve human health and cure diseases.
Kovina Therapeutics operates as a pre-clinical biotechnology company.
IBBR is leverages state-of-art integrative methods for bioanalytical, biophysical and structural characterization of biomolecules.
Melax Technologies specializes in machine learning, software, domain, natural language processing and medical coding services.
Intact Genomics provides high-quality life science products and large DNA fragment cloning related services
Nirvana Science is a technology development company that develops fluorescent dyes with ultra-narrow spectrums.
Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases.
Enrich Therapeutics is a biotechnology startup.
Antibacterial Resistance Leadership Group (ARLG) is a research network for which the Duke Clinical Research Institute
Arisan Therapeutics is a life science company that develops novel solutions for the treatment of neglected and emerging infectious diseases.
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry.
National Institute of Allergy and Infectious Diseases has invested in 64 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
National Institute of Allergy and Infectious Diseases's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Medical. The firm invests across 15 different industry categories.
Among tracked funding rounds, Antibacterial Resistance Leadership Group (ARLG) received $102.5M in a Grant round. National Institute of Allergy and Infectious Diseases's total known invested capital is $242.3M.
National Institute of Allergy and Infectious Diseases's average investment size is $5.0M across its portfolio of 64 companies.
Recent National Institute of Allergy and Infectious Diseases portfolio additions include HDT Bio, Omniose, Ceramedix Holding, Exavir Therapeutics, Truly Technologies. These companies were founded in 2020 or later.